Use your antibodies-online credentials, if available.
Human Polyclonal BCL9L Primary Antibody for WB - ABIN1881110
Miller, Rutherford, Johnson, Fiedler, Bienz: Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor. in Journal of molecular biology 2010
Show all 5 Pubmed References
we identify BCL9L as a novel regulator of TGF-beta (显示 TGFB1 抗体)-induced EMT (显示 ITK 抗体) in pancreatic cancer.
BCL9L dysfunction contributes to aneuploidy tolerance in both TP53 (显示 TP53 抗体)-WT and mutant cells by reducing basal caspase-2 (显示 CASP2 抗体) levels and preventing cleavage of MDM2 (显示 MDM2 抗体) and BID (显示 BID 抗体).
The inhibition of the transcriptional activity of BCL9-2 by WWOX (显示 WWOX 抗体) and HDAC3 (显示 HDAC3 抗体) constitutes a new molecular mechanism and provides new insight for a broad range of cancers.
BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ss-catenin independent mechanism in breast cancer cells.
Data show that beta-cat (显示 GCM1 抗体)enin/BCL9 (显示 ERVW-1 抗体)-Like (BCL9L)/T-cell factor 4 (TCF4) signalling directly targets the GCM1/syncytin pathway and thereby regulates the fusion of human choriocarcinoma cells.
BCL9-2 promotes early phases of intestinal tumor progression in humans and in transgenic mice. BCL9-2 increases the expression of a subset of canonical Wnt (显示 WNT2 抗体) target genes but also regulates genes that are required for early stages of tumor progression.
Pygo2 (显示 PYGO2 抗体) PHD (显示 PDC 抗体) is the only known PHD (显示 PDC 抗体) finger that is capable of interacting simultaneously with two functional ligands, B9L and BCL9 (显示 BCL9 抗体).
crystallographic analysis of how beta-catenin (显示 CTNNB1 抗体), BCL9 (显示 BCL9 抗体), BCL9-2 and Tcf4 (显示 TCF4 抗体) interact
Transcriptional cofactors Bcl9 (显示 BCL9 抗体), Bcl9l and Pygo1 (显示 PYGO1 抗体)/2 act independently of beta-catenin (显示 CTNNB1 抗体) to ensure proper enamel formation.
Data show that the GCM1 (显示 GCM1 抗体)/syncytin (显示 ERVW-1 抗体)-B pathway is significantly downregulated in the placenta of BCL9L-deficient mice and that the fusion and differentiation of ST-II cells are blocked.
We demonstrated that nuclear B9L expression was closely associated with the high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 (显示 ERBB2 抗体) in breast cancers.
BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.
B-cell CLL/lymphoma 9-like protein
, B-cell lymphoma 9-like protein
, BCL9-like protein
, nuclear co-factor of beta-catenin signalling
, protein BCL9-2
, BCL9-related beta-catenin-binding protein
, B-cell CLL/lymphoma 9-like
, b-cell CLL/lymphoma 9-like protein-like